TransCode Therapeutics

RNAZ

Biotechnology · Healthcare

Exchange

NASDAQ Capital Market

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Winston Score History

The full picture

TransCode Therapeutics is a small biotechnology company focused on developing RNA-based medicines to treat cancer. RNA therapies work by delivering genetic instructions into cells to change how they behave — in this case, to fight tumors. The company is working on a platform technology designed to deliver RNA molecules, including microRNA, directly to cancer cells throughout the body.

TransCode is in the early research and development stage, meaning it does not yet sell any products or generate meaningful revenue. It spends money on laboratory research and clinical development, funded primarily through equity raises rather than product sales. The company is based in the United States and is very small, with a market cap near zero, reflecting the high-risk nature of early-stage biotech. The main risk is that it must successfully advance its drug candidates through clinical trials — a process that is expensive, time-consuming, and often fails — before it can generate any commercial revenue.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

-33.7% YoY

YoY Growth Rate

Earnings declining

Insider Activity

8.8%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$8.4B cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Company generates more cash than it spends — no dilution risk from fundraising

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial